Piper Sandler Maintains Neutral on LENZ Therapeutics, Lowers Price Target to $7

Benzinga Newsdesk www.benzinga.com Negative 47.4%

Neg 47.4% Neu 0% Pos 0%

Piper Sandler analyst Biren Amin maintains LENZ Therapeutics (NASDAQ:LENZ) with a Neutral and lowers the price target from $12 to $7.